Loomis, Sayles & Company
INSY

Loomis, Sayles & Company’s Insys Therapeutics, Inc. INSY Stock Holding History

Loomis, Sayles & Company’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-398,827
Closed -$11.4M – 1142
2015
Q3 		$11.4M Sell
398,827
-339,646
-46% -$12.5M 0.03% 412
2015
Q2 		$26.5M Buy
738,473
+82,259
+13% +$2.56M 0.07% 245
2015
Q1 		$19.1M Buy
+656,214
New +$17.4M 0.05% 350

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Loomis, Sayles & Company's INSY Position: Q4 2015 in Review

Loomis, Sayles & Company sold out of Insys Therapeutics, Inc. (INSY) in Q4 2015, closing a stake of 398,827 shares — an estimated $11.4M sold.

Loomis, Sayles & Company first reported a position in INSY in Q1 2015 and held it in 3 quarters. The position peaked at $26.5M in Q2 2015. 154 funds tracked by Wall St. Rank hold INSY as of Q4 2015.

  • Loomis, Sayles & Company reported no remaining Insys Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Loomis, Sayles & Company sold 398,827 Insys Therapeutics, Inc. shares in Q4 2015, an estimated $11.4M.
  • Loomis, Sayles & Company first reported a position in Insys Therapeutics, Inc. in Q1 2015 and held it in 3 quarters.
  • Loomis, Sayles & Company's Insys Therapeutics, Inc. position peaked at $26.5M in Q2 2015.
  • 154 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2015.

Based on Loomis, Sayles & Company's 13F filing for Q4 2015, filed 12 Feb 2016.